Before the Prescription: What a Real BHRT Workup Should Include
If you've spent any time researching hormone replacement therapy for menopause or perimenopause, you've probably noticed how easy it's become to get started. Many telehealth platforms will prescribe estrogen or progesterone based on a symptom checklist alone — hot flashes, mood changes, trouble sleeping — with no blood work at all before the first prescription is sent.
That's faster. It's also missing a step that matters.
Symptoms Overlap — That's the Problem
Hot flashes, fatigue, brain fog, mood changes, and irregular cycles are the classic signs of the menopause transition. They're also the classic signs of thyroid dysfunction, iron deficiency, and several other conditions entirely unrelated to hormone decline.
That overlap is exactly why baseline labs matter before treatment starts, not after. Without them, a clinician has no way to tell whether fatigue is coming from low estrogen, an underactive thyroid, or low iron — and starting hormone therapy without ruling those out means you could spend months treating the wrong problem while the real one goes unaddressed.
What "Baseline" Should Actually Include
A responsible baseline panel goes well beyond a single hormone level. It typically includes a complete blood count, a comprehensive metabolic panel (liver and kidney function, since these organs process and clear hormones), a full thyroid panel, a fasting lipid panel, and fasting glucose or A1c — with sex hormone levels added when the clinical picture calls for it.
The lipid panel specifically isn't optional detail. The Endocrine Society's clinical practice guideline directly recommends lipid screening both before and intermittently during hormone therapy, noting that hormone therapy itself is a factor that can shift LDL and HDL cholesterol. That's not a one-time check-box — it's a marker meant to be revisited.
Why the Baseline Itself Is the Point — Not Just the First Number
Here's what gets lost when a program skips labs entirely: without a true baseline, there's nothing to compare against later. If your estrogen, thyroid, or lipid values shift six months into treatment, a clinician needs to know where you started to know whether that shift is meaningful — or whether it was already like that before you ever began.
This is precisely why the North American Menopause Society's 2022 Hormone Therapy Position Statement calls for individualized treatment plans with periodic reevaluation of a woman's benefit-risk profile — not a single decision made once and never revisited. Hormone therapy formulation, dose, and route are meant to be "determined individually and reassessed periodically," in NAMS's own language — a standard that's simply not achievable without a starting point to measure against.
What This Should Look Like in Practice
A properly run hormone optimization program includes:
A real baseline panel before the first prescription — not a symptom questionnaire standing in for lab work.
Ongoing access to your clinician, not a one-time consult followed by an indefinite auto-refill.
Repeat labs when clinically indicated — to confirm your levels are responding as expected, to catch a lipid or thyroid shift early, and to adjust your dose or formulation based on data, not guesswork.
A route and formulation chosen with your specific labs in mind — for example, women with elevated lipids or liver considerations are often better suited to transdermal estrogen over oral, precisely because of what a baseline panel reveals.
None of this makes hormone therapy more complicated than it needs to be. It makes sure that if your body needs something different six months from now than it did on day one, someone with the right training and your actual data is positioned to catch it — instead of leaving you on the same dose indefinitely, or discovering a problem only after it's become symptomatic on its own.
Ready to start hormone optimization with real data behind it, not just a symptom list?
Head over to our bookings page to begin your consultation.
— Jeffrey D. Schnur, APRN, FNP-BC
Founder & Clinical Director, Apex Coastal Wellness
References & Clinical Guidelines
The North American Menopause Society. (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 29(7), 767–794. (Establishes that hormone therapy formulation, dose, and route should be individualized and reassessed periodically, with risk stratification by age and time since menopause onset.)
Endocrine Society. Lipid Management Guideline. (Recommends lipid screening both before and intermittently during hormone therapy, noting that hormone therapy is a recognized risk factor affecting cardiovascular lipid markers.)
